Metformin

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes. Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an “insulin sensitizer”, leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995. It is grouped under the following drug class(es): Biguanides and Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Fluamine, Haurymelin, Flumamine, Gliguanid and Diaformin. Its PubChem CID is 4091.